What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 5 minute read Pharma Industry News EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story. byPallavi MadhirajuJanuary 31, 2026